Business Context and Reporting Period
Integra LifeSciences Holdings Corporation filed an unaudited Form 10-Q for the three months ended March 31, 2013. The medical-device company operates through U.S. Neurosurgery, U.S. Instruments, U.S. Extremities, U.S. Spine and Other, and International segments, with products spanning orthopedics, neurosurgery, regenerative medicine, wound care, and surgical instruments.
Key Financial Metrics
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Revenue | $196.7 million | $196.2 million | Up $0.5 million |
| Gross profit | $116.4 million | $121.5 million | Down $5.1 million |
| Gross margin | 59.2% | 61.9% | Down 270 basis points |
| Operating income (loss) | $(0.04) million | $17.5 million | Material decline |
| Net income (loss) | $(4.1) million | $6.7 million | Down $10.7 million |
| Diluted EPS | $(0.15) | $0.23 | Declined |
| Operating cash flow | $7.8 million | $32.3 million | Down $24.5 million |
Research and development expense was $12.7 million, or 6.5% of revenue, versus $11.9 million, or 6.1%, in the prior-year quarter. Selling, general and administrative expense increased to $100.2 million from $87.4 million. Interest expense declined to $4.8 million from $7.9 million, primarily following repayment of the 2012 convertible notes in June 2012.
At March 31, 2013, cash and cash equivalents were $89.7 million, down from $96.9 million at year-end 2012. Working capital was $341.3 million. Inventory increased to $179.6 million from $171.8 million, partly reflecting recall-related effects and supply conditions.
Total debt included $321.9 million outstanding under the senior credit facility and $230.0 million principal amount of 1.625% convertible notes due 2016, carried at $199.5 million net of the unamortized discount. Approximately $278.1 million remained available under the credit facility, and the company was in compliance with its covenants at quarter-end.
Material Changes Versus the Prior Comparable Period
- Revenue was broadly flat, but the mix and cost structure deteriorated because of product recalls, supply shortages, remediation costs, and the medical-device excise tax.
- The company recorded a $4.2 million recall-related charge: $2.9 million reduced revenue and $1.3 million increased cost of sales.
- Operating expenses increased by $12.4 million, including higher selling and marketing costs, headcount, consulting expenses, and global ERP implementation costs.
- Segment revenue changes were mixed: U.S. Extremities rose 18% to $31.4 million, while U.S. Neurosurgery declined 3% to $39.0 million, U.S. Instruments declined 3% to $36.9 million, U.S. Spine and Other declined 3% to $43.5 million, and International declined 2% to $45.8 million.
- Operating cash flow declined substantially, primarily because of the net loss and approximately $4.0 million of adverse working-capital changes, including an $8.9 million inventory use of cash.
- The company acquired Tarsus Medical, Inc. on January 24, 2013, for approximately $4.7 million, including $2.8 million of cash and approximately $1.6 million of estimated contingent consideration. The acquisition was not material to consolidated operating results.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected 2013 consolidated gross margin of approximately 60% to 61%, compared with 2012 levels, and targeted full-year research and development expense of approximately 6.5% of revenue.
- Management expected the recall and related supply shortages to reduce revenue in the second and third quarters of 2013, with the greatest impact on U.S. Neurosurgery, U.S. Spine and Other, and International. Most disruptions were expected to be resolved by year-end, but customer losses and elevated backorders remained possible.
- A voluntary recall covered specified collagen-product lots manufactured at the Añasco, Puerto Rico facility. No patient injuries or adverse events had been reported, but shortages and returns reduced first-quarter revenue and were expected to constrain supply for several months.
- The company had FDA warning letters or remediation activities relating to facilities in Plainsboro, New Jersey; Andover, England; and Añasco, Puerto Rico. It expected approximately $2.8 million of additional Plainsboro remediation spending in 2013 and approximately $4.0 million for broader quality-system activities, with completion targeted for the second half of 2013.
- Management expected a full-year effective tax rate of approximately 1.0%, subject to changes in the geographic mix of earnings, tax matters, and available tax credits.
- Planned 2013 capital expenditures were $55 million to $65 million, primarily for regenerative-medicine capacity, plant maintenance, ERP implementation, and orthopedic instrument kits. The company also expected $9 million to $12 million of medical-device excise-tax payments.
- The recall and lower expected profitability were expected to increase the consolidated total leverage ratio. Management warned that a covenant breach could restrict additional borrowings, increase interest costs, and trigger remedies under the credit facility.
- The U.S. Attorney’s Office for the District of New Jersey was investigating alleged improper billing activities by three sales representatives in an extremities region. The company stated it was cooperating voluntarily and was not a subject or target at the filing date.
- Other key risks included FDA and international regulatory compliance, product liability and recalls, reimbursement and pricing pressure, foreign-exchange exposure, supply constraints, healthcare cost containment, and execution of the global ERP implementation.
Most Important Facts for Investors to Verify
- Whether recall-related shortages, product returns, and backorders were resolved as projected and whether additional charges were required.
- Progress and total cost of FDA remediation at the Plainsboro, Andover, and Añasco facilities, including any further regulatory actions.
- Compliance with the senior credit facility’s leverage covenant as earnings and cash flow changed during 2013.
- Actual gross-margin performance relative to the 60%–61% outlook and the effect of the medical-device excise tax.
- Conversion of inventory and receivables into cash, given the decline in operating cash flow and elevated inventory balance.
- Potential financial exposure from the U.S. Attorney’s investigation, product-liability matters, contingent consideration for Tarsus, and other legal contingencies.